Gyroscope Therapeutics, a dry AMD treatment developer exploiting University of Cambridge research, has secured $61.2m from cornerstone investors Cambridge Innovation Capital and Syncona.
Gyroscope Therapeutics, the UK-based developer of a retinal disease treatment based partly on University of Cambridge research, closed a £50.4m ($61.2m) series B round on Monday featuring Cambridge-affiliated patient capital fund Cambridge Innovation Capital (CIC).
Syncona, the life sciences investment trust backed by research charities Wellcome Trust and Cancer Research UK, provided $58.3m to lead the round. CIC contributed the remaining $2.9m to bring its overall investment in Gyroscope to $3.6m.
Founded in 2016, Gyroscope is working on…
